Docetaxel

Land: Neuseeland

Sprache: Englisch

Quelle: Medsafe (Medicines Safety Authority)

Wirkstoff:

Docetaxel trihydrate 25.177mg equivalent to anhydrous docetaxel 20mg

Verfügbar ab:

REX Medical Ltd

INN (Internationale Bezeichnung):

Docetaxel trihydrate 25.177 mg (equivalent to anhydrous docetaxel 20mg)

Dosierung:

20 mg/mL

Darreichungsform:

Concentrate for infusion

Zusammensetzung:

Active: Docetaxel trihydrate 25.177mg equivalent to anhydrous docetaxel 20mg Excipient: Citric acid Polysorbate 80 Ethanol Water for injection

Einheiten im Paket:

Vial, glass, Diluent, 1.5 mL

Klasse:

Prescription

Verschreibungstyp:

Prescription

Hergestellt von:

Cipla Ltd

Anwendungsgebiete:

Docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. Docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. Docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours express HER2 and who previously have not received chemotherapy for metastatic disease.

Produktbesonderheiten:

Package - Contents - Shelf Life: Vial, glass, Diluent - 1.5 mL - 24 months from date of manufacture - Vial, glass, concentrate solution - 20 mg - 24 months from date of manufacture stored at 2° to 8°C (Refrigerate, do not freeze)

Berechtigungsdatum:

2006-06-23